PubRank
Search
About
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients (COMPETE)
Clinical Trial ID NCT02532400
PubWeight™ 0.00
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT02532400
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
2014
9.66
2
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
J Clin Oncol
2012
8.74
3
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
2014
6.76
4
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
2014
5.18
5
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
J Natl Cancer Inst
2005
4.48
6
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Ann Oncol
2015
4.31
7
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
J Clin Oncol
2011
2.71
8
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Lancet Oncol
2012
2.25
9
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Cancer
2007
1.53
Next 100